Meet us at Pharmacon Asia: 23-25 Sept. 2020

Proteona CEO to deliver opening keynote address at the 7th Annual Pharmacon Asia conference Gerd Altmann from Pixabay

Proteona CEO to deliver opening keynote address at the 7th Annual Pharmacon Asia conference

Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology

Dr. Andreas Schmidt, the Chief Executive Officer of Proteona, will deliver the keynote address for the 7th Annual Pharmacon Asia conference on 23 September 2020. Dr. Schmidt will discuss the recent disruptions and opportunities in the pharmaceuticals and healthcare industries, and the potential impact of single cell analysis and artificial intelligence in drug development process.

The Pharmacon Asia conference addresses upcoming trends in the pharma and life sciences and provides a networking platform for companies across Asia and beyond. The 2020 edition comprises three days of talks and workshops on three main topics: digital pharma, regulatory affairs, and market access/pricing.

The Pharmacon Asia event will take place virtually this year.

Meet the speakers at Pharmacon Asia 2020!

Schedule a meeting

For media queries, please contact:

Dr Andreas Schmidt

About Proteona

Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.